Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors:: comparison of two CNI-free protocols

被引:25
作者
Dickmann, Fritz
Gutierrez-Dalmau, Alex
Lopez, Sonia
Cofan, Federico
Esforzado, Naria
Ricart, Maria Jose
Rossich, Esther
Saval, Nfiria
Torregrosa, Jos Vicente
Oppenheirner, Federico
Campistol, Josep M.
机构
[1] Hosp Clin Barcelona, Dept Nephrol & Renal Transplant, E-08036 Barcelona, Spain
[2] Charite Campus Mitte, Dept Nephrol, Berlin, Germany
关键词
calcineurin inhibitor; expanded criteria donors; IL-2 receptor antagonist; mTOR inhibitor; mycophenolate mofetil; proteinuria;
D O I
10.1093/ndt/gfm181
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. The contribution of mammalian target of rapamycin (mTOR) inhibitors to proteinuria, is controversial. The aim was to analyse proteinuria in suboptimal kidney calcineurin inhibitor-(CNI) free de novo immunosuppression. Methods. All patients from our centre with donors > 60 years and CNI-free treatment were included (n = 108). Patients were divided into two groups: (i) SRL group: sirolimus (SRL)+ prednisone+ mycophenolate mofetil (MMF) + antiCD25; (ii) MMF group: prednisone + MMF w/ or w/o antiCD25 (n = 75). Follow-up was 12 months. Results. Donors were slightly younger in the SRL group (68 vs 71 years; P < 0.05), receptor age (67 vs 65 years) was not significantly different. Patient survival in the MMF group was 88 vs 94% in the SRL group, however, these differences did not reach statistical significance. One-year graft survival censored for death was 83% in the MMF group and 94% in the SRL group. Acute rejection rate was 45% in the MMF and 15% in the SRL group (P < 0.01). The incidence of CNI introduction was higher in the MMF-group (35 vs 5; P < 0.05). The intention-to-treat analysis revealed significant differences of proteinuria [SRL vs MMF at 12 months: 461 (163-6988) vs 270 (53-3029) mg/day], which did not exist in the on-therapy (OT) analysis [SRL vs MMF at 12 months: 357 (199-1428) vs 279 (53-3029) mg/day]. New onset nephrotic range proteinuria seemed to occur slightly more frequently in SRL patients (3/33 vs 1/75; P = 0.049), however, all four cases occurred in a context of recurrent disease, or previous drug-independent damage or non-adherence. All of these patients were converted to CNI. Conclusion. SRL-based compared with MMF-based treatment in kidney transplantation with advanced age donors is associated with an acceptable outcome, however, with increased proteinuria in the intention-to-treat analysis. A large subgroup of the patients in the MMF group experienced acute rejection and required conversion to CNI.
引用
收藏
页码:2316 / 2321
页数:6
相关论文
共 13 条
[1]   Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus [J].
Bumbea, V ;
Kamar, N ;
Ribes, D ;
Esposito, L ;
Modesto, A ;
Guitard, J ;
Nasou, G ;
Durand, D ;
Rostaing, L .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (11) :2517-2523
[2]   Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue [J].
Butani, L .
TRANSPLANTATION, 2004, 78 (09) :1362-1366
[3]   Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat [J].
Daniel, C ;
Renders, L ;
Amann, K ;
Schulze-Lohoff, E ;
Hauser, IA ;
Hugo, C .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (12) :2849-2861
[4]   Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction [J].
Diekmann, F ;
Budde, K ;
Oppenheimer, F ;
Fritsche, L ;
Neumayer, HH ;
Campistol, JM .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (11) :1869-1875
[5]   Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy [J].
Dittrich, E ;
Schmaldienst, S ;
Soleiman, A ;
Hörl, WH ;
Pohanka, E .
TRANSPLANT INTERNATIONAL, 2004, 17 (04) :215-220
[6]   De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years [J].
Flechner, SM ;
Kurian, SM ;
Solez, K ;
Cook, DJ ;
Burke, JT ;
Rollin, H ;
Hammond, JA ;
Whisenant, T ;
Lanigan, CM ;
Head, SR ;
Salomon, DR .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (11) :1776-1785
[7]  
LEBRANCHU Y, 2004, TRANSPLANTATION S8, V78, P463
[8]   Proteinuria following a switch from calcineurin inhibitors to sirolimus [J].
Letavernier, E ;
Pe'raldi, MN ;
Pariente, A ;
Morelon, E ;
Legendre, C .
TRANSPLANTATION, 2005, 80 (09) :1198-1203
[9]   Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience [J].
Morelon, E ;
Kreis, H .
TRANSPLANTATION PROCEEDINGS, 2003, 35 (3A) :52S-57S
[10]   Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction [J].
Ruiz, Juan Carlos ;
Campistol, Josep M. ;
Sanchez-Fructuoso, Ana ;
Rivera, Constantino ;
Oliver, Juan ;
Ramos, David ;
Campos, Begona ;
Arias, Manuel ;
Diekmann, Fritz .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (11) :3252-3257